By Amber Burton

Regeneron Pharmaceuticals Inc. (REGN) reported roughly 13% higher revenue and beat expectations for adjusted earnings in the latest quarter.

The biotech company said its fourth-quarter earnings were $792 million, or $6.93 a share, compared with $820 million, or $7.15 a share a year earlier.

Adjusted earnings were $7.50 a share. Analysts polled by FactSet were expecting adjusted earnings of $6.93 a share.

Total revenue was $2.17 billion, up from $1.93 billion a year earlier.

Analysts were expecting revenue of $2.11 billion.

Write to Amber Burton at amber.burton@wsj.com

(END) Dow Jones Newswires

February 06, 2020 06:58 ET (11:58 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Regeneron Pharmaceuticals Charts.